ISHII; Toshihiko

Patent Applications and Registrations

Patent applications and USPTO patent grants for ISHII; Toshihiko.The latest application filed is for "therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody".

Company Profile

0.10.15

ISHII; Toshihiko - Tokyo JP
Ishii; Toshihiko - Shizuoka JP
Ishii; Toshihiko - Sunto-gun JP
Ishii; Toshihiko - Suntogun JP
Ishii; Toshihiko - Tottori JP
Ishii; Toshihiko - Sakura JP

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Therapeutic Agent For A Tumor Comprising An Ido Inhibitor Administered In Combination With An Antibody App 20220088011 - TOKUNAGA; Akihiro ; et al.	2022-03-24
Therapeutic Agent For A Tumor Comprising An Ido Inhibitor Administered In Combination With An Antibody App 20180271861 - TOKUNAGA; Akihiro ; et al.	2018-09-27
RNAi pharmaceutical composition for suppressing expression of KRAS gene Grant 9,913,907 - Naoi , et al. March 13, 2	2018-03-13
Medicament comprising recombinant antibody against chemokine receptor CCR4 Grant 9,675,625 - Shitara , et al. June 13, 2	2017-06-13
Pharmaceutical composition comprising antibody composition which specifically binds to CCR4 Grant 9,387,248 - Ishii , et al. July 12, 2	2016-07-12
Pharmaceutical Composition Comprising Antibody Composition Which Specifically Binds To Ccr4 App 20150147321 - ISHII; Toshihiko ; et al.	2015-05-28
Pharmaceutical composition comprising antibody composition which specifically binds to CCR4 Grant 8,980,263 - Ishii , et al. March 17, 2	2015-03-17
RNAi PHARMACEUTICAL COMPOSITION FOR SUPPRESSING EXPRESSION OF KRAS GENE App 20140044755 - NAOI; Tomoyuki ; et al.	2014-02-13
Composition For Suppressing Expression Of Target Gene App 20140039034 - Shinohara; Fumikazu ; et al.	2014-02-06
Medicament Comprising Recombinant Antibody Against Chemokine Receptor Ccr4 App 20130295045 - SHITARA; Kenya ; et al.	2013-11-07
Pharmaceutical composition comprising antibody composition which specifically binds to CCR4 Grant 8,574,574 - Ishii , et al. November 5, 2	2013-11-05
Pharmaceutical Composition Comprising Antibody Composition Which Specifically Binds To Ccr4 App 20130287768 - ISHII; Toshihiko ; et al.	2013-10-31
Medicament comprising recombinant antibody against chemokine receptor CCR4 Grant 8,491,902 - Shitara , et al. July 23, 2	2013-07-23
Composition For Suppressing Expression Of Target Gene App 20120244210 - SHINOHARA; Fumikazu ; et al.	2012-09-27
Composition For Suppressing Expression Of Target Gene App 20120207818 - SHINOHARA; Fumikazu ; et al.	2012-08-16
Pharmaceutical Composition Comprising Antibody Composition Which Specifically Binds To Ccr4 App 20110262431 - ISHII; Toshihiko ; et al.	2011-10-27
Pharmaceutical Composition Comprising Antibody Composition Which Specifically Binds To Ganglioside Gm2 App 20100111947 - ISHII; Toshihiko ; et al.	2010-05-06
Pharmaceutical Composition App 20100098690 - Soga; Shiro ; et al.	2010-04-22
Method of treating B-cell neoplasms or Hodgkin's lymphoma App 20070172476 - Ueda; Ryuzo ; et al.	2007-07-26
Medicine containing genetically modified antibody against chemokine receptor ccr4 App 20070020263 - Shitara; Kenya ; et al.	2007-01-25
LED array device for printer Grant 4,605,944 - Ishii , et al. August 12, 1	1986-08-12
Process for producing cubic system boron nitride Grant 4,443,420 - Sato , et al. April 17, 1	1984-04-17

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.